Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > llumina and Oxford Nanopore Enter into Broad Commercialization Agreement

Abstract:
Single-Molecule DNA Sequencing System Promises Dramatic Improvement in Cost, Speed, Versatility, and Simplicity of Sequencing

llumina and Oxford Nanopore Enter into Broad Commercialization Agreement

SAN DIEGO, CA and OXFORD, UK | Posted on January 12th, 2009

Illumina (NASDAQ:ILMN) and Oxford Nanopore Technologies ("Oxford Nanopore") today announced a strategic alliance including a commercialization agreement and equity investment. Under the terms of the commercialization agreement, Illumina will exclusively market, sell, distribute, and service BASE™ Technology products developed by Oxford Nanopore for DNA sequencing into the research and diagnostic markets on a worldwide basis. Illumina and Oxford Nanopore will share profits generated from sales.

Oxford Nanopore's new generation sequencing system uses protein nanopores coupled with a processive enzyme. This system is designed for direct electrical identification of DNA bases at the single-molecule level, without the need for fluorescent labels. Currently in development, this technology has the potential to provide substantial advantages over current sequencing approaches, not only in speed and cost but also in simplicity and versatility of overall workflow. The removal of the traditional fluorescent labeling step and reduced burden of sample preparation are highly desirable in future generations of sequencing technology.

As part of the agreement, Illumina made an equity investment of $18.0 million (£11.8 million), which will be used to accelerate the development of BASETM Technology. Illumina has also agreed to make an additional equity investment upon the achievement of a specific technical milestone.

"Oxford Nanopore's technology holds tremendous promise to achieve the sub-$1,000 human genome," said Jay Flatley, President and CEO of Illumina. "Making electrical measurements of unmodified DNA removes the need for complex sample prep and the high-performance optics found in today's sequencing systems. We look forward to a long and productive partnership with Oxford Nanopore."

Oxford Nanopore's CEO, Dr Gordon Sanghera commented, "This alliance brings together today's commercial leader in the field and what we believe will be the future's best sequencing technology. The agreement reflects the rapid progress we have made in developing nanopore technology towards being the first label-free, single-molecule sequencing system. The partnership will enable us to further accelerate our development and enable broad commercialization through Illumina's significant commercial infrastructure."

####

About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina's ability (i) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (ii) to manufacture robust instrumentation and reagents technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.

About Oxford Nanopore Technologies Ltd

Oxford Nanopore was founded in 2005 on the science of Professor Hagan Bayley of the University of Oxford. Since its inception, the Company has focused on developing the pioneering work of Professor Bayley into a mass producible biochip and reader system for molecular analysis. Nanopores have been researched for more than 15 years at a number of the world's most prestigious academic institutions including Harvard, MIT, NIST, the University of Massachusetts, Texas A&M University, and the University of Oxford.

BASETM (Bayley Sequencing) technology uses an adapted protein nanopore coupled with a processive exonuclease enzyme to sequence DNA. The enzyme cleaves individual bases from a strand of DNA, and sequentially introduces the bases into the aperture of the nanopore. An ionic current is continually flowing through the nanopore, and as individual bases travel through the nanopore, each one creates a characteristic disruption in this current. This signal is recorded electronically and interpreted to identify the DNA base. Recordings from multiple channels in parallel allows high-throughput sequencing of DNA.

The technology is label-free and sensitive at the single-molecule level, meaning that it removes the need for fluorescent labels, optical imaging and instrumentation, and the need for complex sample preparation including DNA amplification. By scaling up into a massively parallel sequencing process on an array chip, this method has the potential to deliver dramatic improvements in cost, speed, simplicity and versatility of sequencing.

For more information visit www.nanoporetech.com/sequences.

For more information, please click here

Contacts:
Illumina Media:
Maurissa Bornstein
Public Relations Manager
+1-858-332-4055


Investors:
Peter J. Fromen
Sr. Director
Investor Relations
+1 858.202.4507

or
Oxford Nanopore Technologies
Dr Gordon Sanghera
CEO
Zoe McDougall
Communications
+44 870 486 1966

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014

The Hiden EQP Plasma Diagnostic with on-board MCA July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

Penn Study: Understanding Graphene’s Electrical Properties on an Atomic Level July 22nd, 2014

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Invests in UberSeq, Inc. July 16th, 2014

Harris & Harris Group Portfolio Company D-Wave Systems Closes a $28.4 Million Financing July 14th, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Produced Water Absorbents, Inc. July 9th, 2014

Harris & Harris Group Portfolio Company HZO Raises $20 Million in Growth Financing July 1st, 2014

Nanomedicine

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014

Iranian Scientists Use Nanosensors to Achieve Best Limit for Early Cancer Diagnosis July 19th, 2014

Announcements

Nanometrics Announces Upcoming Investor Events July 22nd, 2014

Bruker Awarded Fourth PeakForce Tapping Patent: AFM Mode Uniquely Combines Highest Resolution Imaging and Material Property Mapping July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

Penn Study: Understanding Graphene’s Electrical Properties on an Atomic Level July 22nd, 2014

Alliances/Partnerships/Distributorships

Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014

Haydale and Goodfellow Announce Major Distribution Agreement for Functionalised Graphene Materials July 21st, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

Martini Tech Inc. becomes the exclusive distributor for Yoshioka Seiko Co. porous chucks for Europe and North America July 20th, 2014

New-Contracts/Sales/Customers

STFC takes delivery of the 100th Hitachi Tabletop SEM in the UK July 3rd, 2014

University of Maastricht Adds Complete Correlative Workflow from FEI to its Institute of Nanoscopy June 23rd, 2014

LatticeGear Sells First LatticeAx 300 Cleaving System to X-FAB: LatticeAx 300 provides fast, accurate cross-sectioning of samples for analysis — more accurately than manual methods and faster and less expensively than automated systems June 9th, 2014

UMass Amherst Purchases Nanonex Advanced 8" NIL Tool NX-2608BA May 28th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE